	PPI+Prokinetics		PPI		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Random, 95% Cl	M-H, Ran	dom, 95% Cl		
Studies only included	d patients wit	h refract	tory GER	D						
Shaheen 2015	71	118	51	122	12.8%	1.44 [1.11, 1.86]				
Yamashita 2019	10	35	5	35	1.1%	2.00 [0.76, 5.25]		+		
Subtotal (95% CI)		153		157	13.8%	1.47 [1.15, 1.88]		•		
Total events	81		56							
Heterogeneity: Tau ² =	= 0.00; Chi ² =	0.43, df	= 1 (P = 1	0.51); P	² = 0%					
Test for overall effect	Z = 3.06 (P =	= 0.002)								
								-		
						0.01	0.1	1	10	100
							Favours [PPI]	Favours [P	PI+Proking	etics]

Supplementary Figure 22. Forest plot of the risk ratio of proton pump inhibitor (PPI) plus prokinetics treatment in reducing global symptoms of refractory gastroesophageal reflux disease. M-H, Mantel-Haenszel.